ASP Isotopes SEC Filings

ASP Isotopes Inc. insider activity: The Interim CEO and COO reported selling 67,500 shares of common stock of ASP Isotopes Inc. on 11/17/2025 at a weighted average price of $7.507 per share. After this transaction, the executive beneficially owns 1,579,693 shares.

The filing explains that the sale was a "sell to cover" transaction made under a Rule 10b5-1 trading plan adopted on June 9, 2025, to cover tax withholding obligations tied to the vesting of restricted stock awards. The shares were sold in multiple trades at prices ranging from $7.215 to $7.85.

ASP Isotopes Inc. (ASPI) reports third-quarter 2025 results reflecting early commercial traction but very heavy losses as it scales its isotope and nuclear fuels platform.

Total revenue reached $4.9 million for the quarter and $7.2 million for the first nine months of 2025, up from $2.95 million a year earlier, driven by both product and new construction services revenue. However, high research and development plus selling, general and administrative costs led to a nine‑month net loss of $96.5 million, compared with $23.2 million in the prior‑year period.

The balance sheet expanded significantly, with cash and cash equivalents of $113.9 million and total assets of $225.9 million as of September 30, 2025, supported by two common stock offerings in June and July 2025 and additional capital raised in October and November. Convertible notes payable at fair value increased to $98.0 million, and total stockholders’ equity rose to $96.6 million.

ASP Isotopes has begun commercial production at two enrichment facilities in South Africa and is preparing initial shipments of enriched C‑12, Si‑28 and C‑14 between late 2025 and the first half of 2026, while also producing Yb‑176 samples. The company is planning additional plants in South Africa, Iceland and the U.S., pursuing a uranium‑235 nuclear fuel initiative, a pending acquisition of Renergen, and a planned spin‑off and U.S. listing of its Quantum Leap Energy (QLE) business, for which a confidential S‑1 has been submitted.

ASP Isotopes Inc. reported that it will host a quarterly business update conference call and webcast on November 21, 2025 at 8:30 a.m. Eastern Time. The company disclosed this plan in a current report and attached the related press release as an exhibit, noting that the call will provide a regular update on its business activities. The press release is furnished for information purposes and is not treated as filed under securities law.

ASP Isotopes Inc. reports that its wholly owned subsidiary Quantum Leap Energy LLC plans to issue approximately $64.3 million of unsecured convertible promissory notes to accredited and non-U.S. investors. The QLE 2025 Notes bear 8.0% annual interest, with principal and interest due on demand by majority noteholders on or after the five-year anniversary of the initial closing. QLE expects to use the net proceeds to build and develop laser enrichment production facilities and for general corporate purposes.

Existing 2024 convertible notes will automatically convert into QLE 2025 Notes at the initial closing, without additional proceeds to QLE or ASPI. The notes convert into equity upon a stock exchange listing, a qualifying equity financing of at least $20 million, certain corporate transactions, or at maturity, generally at a 20% discount or a valuation-based price formula. Holders who do not convert in a qualifying corporate transaction are entitled to unpaid interest plus 1.5× principal. A registration rights agreement will grant demand and piggyback registration rights, including the ability to demand an initial public offering if QLE has not gone public within five years.

ASP Isotopes Inc. (ASPI) announced that its wholly owned subsidiary, Quantum Leap Energy LLC (QLE), has confidentially submitted a draft registration statement on Form S-1 to the SEC for a proposed initial public offering of QLE’s Class A common stock.

The disclosure was furnished under Item 7.01 (Regulation FD) and, along with the accompanying press release, was issued pursuant to Rule 135. The notice states it does not constitute an offer to sell or a solicitation to buy any securities and will be subject to the registration requirements of the Securities Act.

ASP Isotopes (ASPI) furnished an update on its subsidiary financing. Quantum Leap Energy (QLE), a wholly owned subsidiary, issued an investor presentation and commenced a private placement of QLE convertible promissory notes. QLE entered a definitive purchase agreement for an initial closing of $64.3 million of QLE Notes, led by American Ventures LLC, with ASP Isotopes also making a significant investment. QLE may issue additional notes in subsequent closings to non‑U.S. persons in transactions outside the United States in reliance on Regulation S.

The investor presentation (Exhibit 99.1) and a press release (Exhibit 99.2) are included as exhibits. The information was furnished under Regulation FD and is not deemed filed under the Exchange Act.

ASP Isotopes Inc. (ASPI) reported a corporate update. The company announced that its U.K. subsidiary, Quantum Leap Energy Ltd., has commenced early engagement for regulatory pathways with U.K. nuclear regulators.

The announcement was made via a press release, which is furnished as Exhibit 99.1 and incorporated by reference in this report, other than the fourth and eighth paragraphs of that press release.

ASP Isotopes (ASPI)Quantum Leap Energy LLC, has completed the purchase of certain assets from One 30 Seven Inc. to advance solutions for processing nuclear waste. The company furnished this update under Item 8.01 and attached a press release as Exhibit 99.1, noting that the ninth paragraph of the release is not incorporated by reference.

ASP Isotopes Inc. (ASPI) launched a primary offering of common stock under an automatic shelf, registering $210,300,405 of shares. The underwriting allocation lists 17,167,380 shares, and the underwriters agreed to purchase at $11.65 per share, yielding approximately $200.0 million in gross proceeds to the company before expenses. Net proceeds are estimated at $199.7 million, with a 30‑day option for up to $31,545,048 of additional shares; if fully exercised, total proceeds before expenses would be about $230.0 million.

The company plans to use proceeds for general corporate purposes, including working capital, operating expenses, and capital expenditures. ASPI notes recent operating losses and expects existing cash plus the July 2025 raise and this offering to fund operations for more than 12 months from the June 30, 2025 financial statement date. Shares outstanding were 93,406,629 as of October 10, 2025. Underwriter lock-ups apply, and the shares are listed on Nasdaq under “ASPI”.